Properties (57)
Predicate | Object |
---|---|
gptkbp:instanceOf |
monoclonal antibody
|
gptkbp:administrativeDivision |
every 2 weeks
every 4 weeks after initial treatment |
gptkbp:approves |
gptkb:FDA
|
gptkbp:clinicalTrials |
ongoing
Phase II Phase III Phase I first-line therapy second-line therapy |
gptkbp:contraindication |
hepatitis
autoimmune diseases pneumonitis colitis endocrinopathies history of severe hypersensitivity |
gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
gptkbp:dosageForm |
3 mg/kg every 2 weeks
|
gptkbp:drugInterdiction |
long half-life
increases T-cell activity |
gptkbp:formulation |
solution for infusion
|
gptkbp:hasCapacity |
educational resources
financial assistance programs nurse helpline |
gptkbp:hasPopulation |
adults
pediatric patients in trials |
https://www.w3.org/2000/01/rdf-schema#label |
Nivolumab
|
gptkbp:interactsWith |
corticosteroids
other immunotherapies |
gptkbp:is_monitored_by |
liver function tests
thyroid function tests |
gptkbp:issuedBy |
intravenous infusion
|
gptkbp:lastProduced |
2014
|
gptkbp:mandates |
gptkb:melanoma
renal cell carcinoma non-small cell lung cancer |
gptkbp:marketedAs |
gptkb:Opdivo
|
gptkbp:patentStatus |
patented
expiring in 2026 |
gptkbp:researchAreas |
combination therapies
biomarkers for response |
gptkbp:researchInterest |
improved overall survival
durable responses less toxicity than chemotherapy |
gptkbp:resources |
ASCO guidelines
NCCN_guidelines |
gptkbp:route |
intravenous
|
gptkbp:sideEffect |
fatigue
diarrhea rash immune-related adverse events |
gptkbp:storage |
refrigerated
protected from light |
gptkbp:targets |
PD-1
|
gptkbp:triggerType |
immune checkpoint inhibitor
|
gptkbp:usedFor |
treatment of cancer
|
gptkbp:variant |
ipilimumab
|